Processing....
SRI International has secured a seven-year, $150 million contract from the National Institutes of Health to provide development services for candidate HIV prevention products from investigator-initiated studies or from partnerships with other companies and organizations. SRI said Tuesday its biosciences division will manufact...
The International AIDS Vaccine Initiative has received a potential seven-year, $98 million contract from the National Institutes of Health to support the agency’s efforts to develop a vaccine against the disease. IAVI will work with NIH’s National Institute of Allergy and Infectious Diseases to characterize and pr...
The National Institute of Allergy and Infectious Diseases has awarded a division of SRI International a potential five-year, $100 million contract to develop therapies for radiation exposure. SRI Biosciences will carry out preclinical testing, good manufacturing practice development, stability studies, human clinical trials and formulation developme...
The Department of Health and Human Services has tapped Emergent BioSolutions to further develop a new anthrax vaccine under a 30-month, $31 million contract with funding and technical support from the Biomedical Advanced Research and Development Authority. HHS said Monday the new vaccine, calledÂ...
